Please use this identifier to cite or link to this item:
https://doi.org/10.1016/j.ejphar.2005.07.033
DC Field | Value | |
---|---|---|
dc.title | Novel neuroprotective effects with O-benzyl derivative of pralidoxime in soman-intoxicated rodents | |
dc.contributor.author | Loke, W.-K. | |
dc.contributor.author | Sim, M.-K. | |
dc.contributor.author | Go, M.-L. | |
dc.date.accessioned | 2014-10-29T01:56:11Z | |
dc.date.available | 2014-10-29T01:56:11Z | |
dc.date.issued | 2005-10-03 | |
dc.identifier.citation | Loke, W.-K., Sim, M.-K., Go, M.-L. (2005-10-03). Novel neuroprotective effects with O-benzyl derivative of pralidoxime in soman-intoxicated rodents. European Journal of Pharmacology 521 (1-3) : 59-69. ScholarBank@NUS Repository. https://doi.org/10.1016/j.ejphar.2005.07.033 | |
dc.identifier.issn | 00142999 | |
dc.identifier.uri | http://scholarbank.nus.edu.sg/handle/10635/106176 | |
dc.description.abstract | Pharmacological properties of oxime reactivators, not related to its ability to regenerate or reactivate nerve agent-inhibited acetylcholinesterase located at nerve synapses, have been reported to be important in protecting against poisoning by the nerve agent soman. Such non-reactivation effects have thus far been associated only with bispyridinium oximes. This study investigated the possibility of creating similar non-reactivation therapeutic effects in the mono-pyridinium ring oxime, pralidoxime (2-PAM) through attachment of alkyl groups of increasing chain length to the oxime functional group. Of the 4 derivatives investigated, only the O-benzyl derivative displayed strong sedative effects in mice and mitigated the development of motor convulsions following soman challenge (1.8 × LD50, subcutaneous). Anticonvulsant effects of this compound were enhanced by co-administration of a non-anticonvulsant dose of atropine sulfate. Administration of equivalent amount of other O-derivatives of pralidoxime failed to elicit similar anticonvulsant actions. Electroencephalographic (EEG) and histopathological studies using the rat model, intoxicated with a lethal dose (1.6 × LD50, s.c.) of soman, confirmed O-benzyl derivative neuroprotective capabilities when used as a pretreatment drug. Microdialysis studies revealed that its neuroprotective effect is related to its ability to attenuate soman-induced increase in acetylcholine. © 2005 Elsevier B.V. All rights reserved. | |
dc.description.uri | http://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.1016/j.ejphar.2005.07.033 | |
dc.source | Scopus | |
dc.subject | Acetylcholine | |
dc.subject | Anticonvulsant effect | |
dc.subject | Non-reactivation effect | |
dc.subject | Pralidoxime derivative | |
dc.subject | Sedative effect | |
dc.subject | Soman poisoning | |
dc.type | Article | |
dc.contributor.department | PHARMACY | |
dc.description.doi | 10.1016/j.ejphar.2005.07.033 | |
dc.description.sourcetitle | European Journal of Pharmacology | |
dc.description.volume | 521 | |
dc.description.issue | 1-3 | |
dc.description.page | 59-69 | |
dc.description.coden | EJPHA | |
dc.identifier.isiut | 000232869700009 | |
Appears in Collections: | Staff Publications |
Show simple item record
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.